Axonics (AXNX)
(Delayed Data from NSDQ)
$70.24 USD
-0.04 (-0.06%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $70.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.24 USD
-0.04 (-0.06%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $70.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Zacks News
Fulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BOX Gears Up for Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
BOX's fourth-quarter fiscal 2023 results are likely to reflect strength in its Content Cloud amid headwinds.
Why Axonics (AXNX) Might Surprise This Earnings Season
by Zacks Equity Research
Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Agilent Technologies (A) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Agilent Technologies (A) first-quarter fiscal 2023 results are likely to reflect strength in LSAG, ACG and DGG segments.
Coupang (CPNG) to Release Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Coupan's (CPNG) fourth-quarter results are expected to reflect strength in its logistics and e-commerce businesses.
MercadoLibre (MELI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
MercadoLibre's (MELI) fourth-quarter results are likely to reflect strength in the commerce and fintech businesses.
Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Booking Holdings (BKNG) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Booking Holdings' (BKNG) fourth-quarter results are likely to reflect gains from strength in the agency, advertisement and merchant businesses.
Block (SQ) to Release Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Block's (SQ) fourth-quarter results are likely to reflect portfolio strength amid the coronavirus pandemic.
What's in the Offing for Alibaba (BABA) in Q3 Earnings?
by Zacks Equity Research
Alibaba's (BABA) third-quarter fiscal 2023 results are expected to reflect gains from its International commerce and Cloud segments.
Axonics (AXNX) Soars 10.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
3 Hot Stocks Going Into the Holiday Weekend
by Derek Lewis
All three of these top-ranked stocks have recently gone on nice runs, giving shareholders some holiday cheer. Can the strength spill over into the new year?
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Axonics (AXNX) This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 27.66% and 12.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Is a Surprise Coming for Axonics (AXNX) This Earnings Season?
by Zacks Equity Research
Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Enovis (ENOV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info System Stocks to Gain on Rising Demand for Digital Health
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
Axonics Inc. (AXNX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Axonics (AXNX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.